Lefamulin acetate

From WikiMD.org
Jump to navigation Jump to search

Lefamulin Acetate

Lefamulin acetate (pronunciation: leh-fam-yoo-lin a-seh-tate) is a semi-synthetic pleuromutilin antibiotic developed for the treatment of community-acquired bacterial pneumonia (CABP). It is marketed under the brand name Xenleta by Nabriva Therapeutics.

Etymology

The name "Lefamulin" is derived from the class of antibiotics it belongs to, pleuromutilins, and "acetate" refers to the salt form of the drug.

Pharmacology

Lefamulin acetate works by inhibiting the synthesis of bacterial protein, which is essential for bacteria growth and reproduction. It binds to the peptidyl transferase center (PTC) on the 50S subunit of the bacterial ribosome, thereby inhibiting protein synthesis and leading to bacterial cell death.

Clinical Use

Lefamulin acetate is indicated for the treatment of adults with community-acquired bacterial pneumonia caused by susceptible isolates of designated microorganisms. It is administered either orally or intravenously.

Side Effects

Common side effects of Lefamulin acetate include diarrhea, nausea, reactions at the injection site, elevated liver enzymes, and insomnia. Serious side effects may include Clostridium difficile-associated diarrhea and QT prolongation.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski